Bioline Rx Overview
Bioline Rx (BLRX) has a ROE of -111.99%, below the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow-111.99%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Bioline Rx (BLRX) currently reports a ROE of -111.99%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore Bioline Rx's ROE history and peer comparisons.
Bioline Rx's ROE of -111.99% is lower than the Healthcare sector average of -100.59%. That is roughly 11.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Bioline Rx's current -111.99% should be judged against Healthcare norms (sector average: -100.59%) and against BLRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -111.99%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Bioline Rx, and consider following BLRX for alerts when major investors trade the stock.
Bioline Rx is classified in the Healthcare sector. On ROE, it currently shows -111.99% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BLRX with unrelated industries.
